Psoriatic arthritis: Pharmacoeconomic considerations

Current Rheumatology Reports

Volumn 11, Issue 4, 2009, Pages 263-269

  Olivieri, Ignazio ^a   Mantovani, Lorenzo Giovanni ^b   D'Angelo, Salvatore ^b   Padula, Angela ^b   De Portu, Simona ^b  

^a SAN CARLO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG COST; FUNCTIONAL STATUS; HEALTH INSURANCE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; JOINT INJURY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL SYSTEM; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; SKIN MANIFESTATION;

ARTHRITIS, PSORIATIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449631451     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0037-x     Document Type: Review

References (50)

1. G.H. Mooney M.F. Drummond 1982 Essentials of health economics: Part I. What is economics Br Med J (Clin Res Ed) 285 949 950 10.1136/bmj.285.6346.949 1:STN:280:DyaL3s%2FgtFantQ%3D%3D
2. Drummond MF, Sculpher MJ, Torrance GW, et al.: Methods for the Economic Evaluation of Health Care Programmes, edn 3. Oxford, United Kingdom: Oxford University Press; 2005.
3. National Center of Health Statistics: 1996. Healthy people review. Hyattsville, MD: Public Health Service; 1995-1996.
4. C.J. Murray A.D. Lopez 1997 Global mortality, disability, and contribution of risk factors: Global Burden of Disease Study Lancet 349 1436 1442 9164317 10.1016/S0140-6736(96)07495-8 1:STN:280:DyaK2szgslWjtg%3D%3D (Pubitemid 27212192)
5. N.J. McHugh C. Balachrishnan S.M. Jones 2003 Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study Rheumatology (Oxford) 42 778 783 10.1093/rheumatology/keg217 1:STN:280:DC%2BD3s3kvVGltA%3D%3D (Pubitemid 37220911)
6. D.D. Gladman F. Stafford-Brady C.H. Chang, et al. 1990 Longitudinal study of clinical and radiological progression in psoriatic arthritis J Rheumatol 17 809 812 2388203 1:STN:280:DyaK3czlsFSqsA%3D%3D
7. J.C. Torre-Alonso A. Rodriguez-Perez J.M. Arribas Castrillo, et al. 1991 Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients Br J Rheumatol 30 245 250 1863819 10.1093/rheumatology/30.4.245 1:STN:280:DyaK3Mzit1Kjug%3D%3D
8. D. Kane L. Stafford B. Bresnihan O. FitzGerald 2003 A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience Rheumatology (Oxford) 42 1460 1468 10.1093/rheumatology/ keg384 1:STN:280:DC%2BD3srntFyhtw%3D%3D (Pubitemid 37508919)
9. C. Palazzi L. D'Agostino E. D'Amico, et al. 2003 Asymptomatic erosive peripheral psoriatic arthritis: a frequent finding in Italian patients Rheumatology (Oxford) 42 909 911 10.1093/rheumatology/keg222 1:STN:280:DC%2BD3s3pvFKrsQ%3D%3D (Pubitemid 37220948)
10. R. Scarpa A. Cuocolo R. Peluso, et al. 2008 Early psoriatic arthritis: the clinical spectrum J Rheumatol 35 137 141 18050372
11. U.R. Lindqvist G.M. Alenius T. Husmark, et al. 2008 The Swedish early psoriatic arthritis register-2-year follow-up: a comparison with early rheumatoid arthritis J Rheumatol 35 668 673 18278834
12. J.A. Husted D.D. Gladman V.T. Farewell, et al. 1997 Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis J Rheumatol 24 511 517 9058658 1:STN:280:DyaK2s3htFKqsw%3D%3D
13. Gladman DD: Disability and quality of life considerations. Psoriatic arthritis. In Psoriatic and Psoriatic Arthritis: An Integral Approach. Edited by Gordon GB, Ruderman E. Heidelberg, Germany: Springer-Verlag; 2005:118-123.
14. Drummond MF, O'Brien B, Stoddard GL, Torrance GW: Method for the Economic Evaluation in Health Care Programmes, edn 2. Oxford, United Kingdom: Oxford University Press; 1997.
15. N.J. Bansback R. Ara N. Barkham, et al. 2006 Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis Rheumatology (Oxford) 45 1029 1038 10.1093/rheumatology/ kel147 1:CAS:528:DC%2BD28Xotl2rsrw%3D (Pubitemid 44283062)
16. M. Eandi C. Salvarani 2006 Pharmacoeconomic analysis of biological drugs for the treatment of psoriatic arthritis [in Italian] Farmacoeconomia e Percorsi Terapeutici 7 171 186
17. N. Woolacott Y. Bravo Vergel N. Hawkins, et al. 2006 Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Health Technol Assess 10 1 239 17083854 1:STN:280: DC%2BD28nltVKqsA%3D%3D
18. A. Kavanaugh C. Antoni P. Mease, et al. 2006 Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis J Rheumatol 33 2254 2259 16960923 1:CAS:528:DC%2BD28Xhtlemu77E
19. Y. Bravo Vergel N.S. Hawkins K. Claxton, et al. 2007 The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis Rheumatology 46 1729 1735 17956918 10.1093/ rheumatology/kem221 1:CAS:528:DC%2BD2sXht1ejtbjO (Pubitemid 350018498)
20. I. Olivieri S. de Portu C. Salvarani, et al. 2008 The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy Rheumatology 47 1664 1670 18725374 10.1093/rheumatology/ ken320 1:STN:280:DC%2BD1cnmvFKgsg%3D%3D
21. S. Sizto N. Bansback S.R. Feldman, et al. 2009 Economic evaluation of systemic therapies for moderate to severe psoriasis Br J Dermatol 160 1264 1272 19120346 10.1111/j.1365-2133.2008.08962.x 1:CAS:528:DC%2BD1MXotlSitrk%3D
22. K.B. Sokoll P.S. Helliwell 2001 Comparison of disability and quality of life in rheumatoid and psoriatic arthritis J Rheumatol 28 1842 1846 11508587 1:STN:280:DC%2BD3Mvmtlahsg%3D%3D
23. Gladman DD: Psoriatic arthritis. In Kelley's Textbook of Rheumatology, edn 7. Edited by Harris ED Jr, Budd RC, Firestein GS, et al.: Philadelphia: Elsevier Saunders; 2005:1155-1164.
24. R. Queiro J.C. Torre J. Belzunegui, et al. 2002 Clinical features and predictive factors in psoriatic arthritis-related uveitis Semin Arthritis Rheum 31 264 270 11836659 10.1053/sarh.2002.28798 (Pubitemid 34160810)
25. R. Scarpa F. Manguso A. D'Arienzo, et al. 2000 Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms J Rheumatol 27 1241 1246 10813294 1:STN:280: DC%2BD3c3ntFCjsA%3D%3D
26. L. Mallbris C.T. Ritchlin M. Ståle 2006 Metabolic disorders in patients with psoriasis and psoriatic arthritis Curr Rheumatol Rep 8 355 363 16973109 10.1007/s11926-006-0065-8 1:CAS:528:DC%2BD28XhtFGrt7fN (Pubitemid 44638828)
27. A.L. Neimann D.B. Shin X. Wang, et al. 2006 Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 829 835 17052489 10.1016/j.jaad.2006.08.040 (Pubitemid 44556851)
28. L.S. Tam B. Tomlinson T.T. Chu, et al. 2008 Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation Rheumatology (Oxford) 47 718 723 10.1093/rheumatology/ken090 (Pubitemid 351619219)
29. R. Scarpa F. Ayala N. Caporaso I. Olivieri 2006 Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33 210 212 16465649
30. C. Ritchlin 2007 Psoriatic disease-from skin to bone Nat Clin Pract Rheumatol 3 698 706 18037929 10.1038/ncprheum0670 1:CAS:528:DC%2BD2sXhtlCqsrzP (Pubitemid 350187015)
31. C. Ritchlin 2008 From skin to bone: translational perspectives on psoriatic disease J Rheumatol 35 1434 1437 18609740
32. M. Dougados S. van der Linden R. Juhlin, et al. 1991 The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy Arthritis Rheum 34 1218 1227 1930310 10.1002/art.1780341003 1:STN:280:DyaK38%2FivFSqsA%3D%3D
33. I. Olivieri A. van Tubergen C. Salvarani S. van der Linden 2002 Seronegative spondyloarthritides Best Pract Res Clin Rheumatol 16 723 739 12473270 10.1053/berh.2002.0263
34. K. Wong D.D. Gladman J. Husted, et al. 1997 Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death Arthritis Rheum 40 1868 1872 9336423 10.1002/art.1780401021 1:STN:280:DyaK2svns1WksA%3D%3D (Pubitemid 27452539)
35. D.D. Gladman V.T. Farewell K. Wong J. Husted 1998 Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death Arthritis Rheum 41 1103 1110 9627021 10.1002/1529- 0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N 1:STN:280:DyaK1c3ovVOisg%3D%3D (Pubitemid 28265412)
36. P.J. Mease A.J. Kivitz F.X. Burch, et al. 2004 Etanercept treatment of psoriatic arthritis. Safety, efficacy, and effect on disease progression Arthritis Rheum 50 2264 2272 15248226 10.1002/art.20335 1:CAS:528: DC%2BD2cXmsVansbc%3D (Pubitemid 38924405)
37. A. Kavanaugh C. Antoni D.D. Gladman, et al. 2006 The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year Ann Rheum Dis 65 1038 1043 16439444 10.1136/ard.2005.045658 1:CAS:528:DC%2BD28XosFahurk%3D (Pubitemid 44133266)
38. P. Mease D.D. Gladman C.T. Ritchlin, et al. 2005 Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 3279 3289 16200601 10.1002/art.21306 1:CAS:528:DC%2BD2MXhtF2msrjP (Pubitemid 41447111)
39. J. Zochling D. van der Heijde M. Dougados J. Braun 2006 Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis Ann Rheum Dis 65 423 432 16126792 10.1136/ard.2005.041129 1:CAS:528:DC%2BD28XjslWjtLk%3D
40. Ritchlin CT, Kavanaugh A, Gladman DD, et al.: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2008 Oct 24 (Epub ahead of print).
41. I. Olivieri S. D'Angelo C. Palazzi A. Padula 2009 Treatment strategies for early psoriatic arthritis Expert Opin Pharmacother 10 271 282 19236198 10.1517/14656560802653198 1:CAS:528:DC%2BD1MXntlOmug%3D%3D
42. H.S. Javitz M.M. Ward E. Farber, et al. 2002 The direct cost of care for psoriasis and psoriatic arthritis in the United States J Am Acad Dermatol 46 850 860 12063481 10.1067/mjd.2002.119669
43. D. Huscher S. Merkesdal K. Thiele, et al. 2006 Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany Ann Rheum Dis 65 1175 1183 16540552 10.1136/ard.2005.046367 1:STN:280:DC%2BD28vnvFKqtQ%3D%3D (Pubitemid 44277392)
44. K.K. Kraning G.F. Odland 1979 Psoriasis J Invest Dermatol 73 402 413 10.1111/1523-1747.ep12541120
45. G.G. Krueger P.R. Bergstresser N.J. Lowe, et al. 1984 Psoriasis J Am Acad Dermatol 11 937 947 6389615 10.1016/S0190-9622(84)80018-3 1:STN:280: DyaL2M%2FlsFKhsA%3D%3D
46. C. Ackermann A. Kavanaugh 2008 Economic burden of psoriatic arthritis Pharmacoeconomics 26 121 129 18198932 10.2165/00019053-200826020-00003
47. A. Kavanaugh 2005 Health economics: implications for novel antirheumatic therapies Ann Rheum Dis 64 iv65 69 16239392 10.1136/ard.2005.042440 (Pubitemid 41532023)
48. A. Kavanaugh 2006 Pharmacoeconomic considerations in the treatment of psoriatic arthritis Rheumatology (Oxford) 45 790 791 10.1093/rheumatology/kel153 1:STN:280:DC%2BD28zotlSgtg%3D%3D (Pubitemid 43985363)
49. A. Messori B. Santarlasci S. Trippoli M. Vaiani 2003 Drug economic equivalent and clinical benefit: state of the art on methodology and application of a pharmacoeconomic algorithm Pharmacoeconomics-Italian Research Articles 5 53 67
50. A.B. Kimball J.M. Jackson J.M. Sobell, et al. 2007 Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial J Drugs Dermatol 6 299 306 17373192